Stuart K Roberts

Summary

Affiliation: Alfred Hospital
Country: Australia

Publications

  1. doi request reprint Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C
    Stuart K Roberts
    The Alfred Hospital, Melbourne, Australia
    Hepatology 48:398-406. 2008
  2. ncbi request reprint Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis
    Stuart Roberts
    Department of Gastroenterology, Alfred Hospital, Melbourne, Victoria, Australia
    Clin Gastroenterol Hepatol 5:932-7. 2007
  3. doi request reprint Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial
    Stuart K Roberts
    The Alfred, Melbourne, Australia
    Hepatology 50:1045-55. 2009
  4. ncbi request reprint Hepatocellular carcinoma in an Australian tertiary referral hospital 1975-2002: change in epidemiology and clinical presentation
    Stuart K Roberts
    Department of Gastroenterology The Alfred, Melbourne, Victoria, Australia
    J Gastroenterol Hepatol 22:191-6. 2007
  5. doi request reprint Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection
    Matthew T Kitson
    Alfred Hospital, Melbourne, Australia
    J Hepatol 58:467-72. 2013
  6. doi request reprint Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1
    William Sievert
    Gastroenterology and Hepatology Unit, Monash Medical Centre and Centre for Inflammatory Diseases, Monash University, Melbourne, Vic, Australia
    Hepatology 53:1109-17. 2011
  7. doi request reprint GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease
    Mark D Berzsenyi
    Department of Gastroenterology, Alfred Hospital, Prahran, Victoria, Australia
    J Gastroenterol Hepatol 24:1407-10. 2009
  8. doi request reprint Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease
    Mark D Berzsenyi
    Department of Gastroenterology, Alfred Hospital, Commercial Road, Prahran, 3181 Victoria, Australia
    J Hepatol 55:536-44. 2011
  9. doi request reprint A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease
    Stephen P Casey
    Departments of Gastroenterology, Alfred Hospital, Melbourne, Vic, Australia
    Scand J Gastroenterol 47:836-41. 2012
  10. ncbi request reprint Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease
    William Kemp
    Department of Gastroenterology, Alfred Hospital, Commercial Road, Prahran, Victoria 3181, Australia
    J Gastroenterol Hepatol 20:873-81. 2005

Collaborators

Detail Information

Publications34

  1. doi request reprint Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C
    Stuart K Roberts
    The Alfred Hospital, Melbourne, Australia
    Hepatology 48:398-406. 2008
    ..Conclusion: These data support further studies of R1626 in combination with peginterferon alfa-2a and ribavirin for the treatment of patients with chronic HCV infection...
  2. ncbi request reprint Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis
    Stuart Roberts
    Department of Gastroenterology, Alfred Hospital, Melbourne, Victoria, Australia
    Clin Gastroenterol Hepatol 5:932-7. 2007
    ..The aims of this study were to investigate the effect of treatment with peginterferon alfa-2a and ribavirin on hepatic venous pressure gradient (HVPG) in CHC with compensated cirrhosis...
  3. doi request reprint Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial
    Stuart K Roberts
    The Alfred, Melbourne, Australia
    Hepatology 50:1045-55. 2009
    ..The high SVR rates in patients with minimal fibrosis highlight the benefit of early treatment in patients with hepatitis C virus genotype 1...
  4. ncbi request reprint Hepatocellular carcinoma in an Australian tertiary referral hospital 1975-2002: change in epidemiology and clinical presentation
    Stuart K Roberts
    Department of Gastroenterology The Alfred, Melbourne, Victoria, Australia
    J Gastroenterol Hepatol 22:191-6. 2007
    ..We compared the epidemiology and clinical features of hepatocellular carcinoma (HCC) cases diagnosed between 1975 and 2002...
  5. doi request reprint Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection
    Matthew T Kitson
    Alfred Hospital, Melbourne, Australia
    J Hepatol 58:467-72. 2013
    ....
  6. doi request reprint Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1
    William Sievert
    Gastroenterology and Hepatology Unit, Monash Medical Centre and Centre for Inflammatory Diseases, Monash University, Melbourne, Vic, Australia
    Hepatology 53:1109-17. 2011
    ..Patients who first developed a hemoglobin decline >30 g/L during weeks 5-12 and 13-48 were more likely to achieve SVR than those who first developed such changes in weeks 0-4 or who never experienced them...
  7. doi request reprint GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease
    Mark D Berzsenyi
    Department of Gastroenterology, Alfred Hospital, Prahran, Victoria, Australia
    J Gastroenterol Hepatol 24:1407-10. 2009
    ..The aim of the present study was to identify the GBV-C genotype in a HCV/HIV co-infected population and determine if the GBV-C genotype contributes to a reduction in HCV-related liver disease...
  8. doi request reprint Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease
    Mark D Berzsenyi
    Department of Gastroenterology, Alfred Hospital, Commercial Road, Prahran, 3181 Victoria, Australia
    J Hepatol 55:536-44. 2011
    ..Considering that the underlying mechanism(s) are unknown, we aim to identify differential gene and protein expression associated with GBV-C in HCV/HIV co-infection that may be responsible for reduced liver disease...
  9. doi request reprint A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease
    Stephen P Casey
    Departments of Gastroenterology, Alfred Hospital, Melbourne, Vic, Australia
    Scand J Gastroenterol 47:836-41. 2012
    ..Transient elastography (TE) is a rapid, reproducible non-invasive test that may be appropriate as a screening tool for the presence of hepatic fibrosis...
  10. ncbi request reprint Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease
    William Kemp
    Department of Gastroenterology, Alfred Hospital, Commercial Road, Prahran, Victoria 3181, Australia
    J Gastroenterol Hepatol 20:873-81. 2005
    ....
  11. ncbi request reprint Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection
    Mark D Berzsenyi
    Department of Gastroenterology, Alfred Hospital, Prahran, Victoria, Australia
    Gastroenterology 133:1821-30. 2007
    ..However, GBV-C has no effect on the course of liver disease in hepatitis C virus (HCV) monoinfection. The aim of the study was to determine the influence of GBV-C infection on liver disease in patients with HCV/HIV coinfection...
  12. ncbi request reprint Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C
    Adam Gordon
    Department of Gastroenterology, Alfred Hospital, Commercial Road, Prahran, Victoria 3181, Australia
    J Gastroenterol Hepatol 20:825-32. 2005
    ..Thus, the aims of the present study were to compare separately and in combination, clinical markers of liver disease, the discriminant score (DS) and serum hyaluronic acid (HA) for their ability to predict cirrhosis in CHC...
  13. ncbi request reprint Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C
    Adam Gordon
    Department of Gastroenterology, The Alfred Hospital, Victoria, Australia
    J Gastroenterol Hepatol 21:275-80. 2006
    ..The aims of this pilot study were to assess the efficacy and safety of S. marianum on serum hepatitis C virus (HCV) RNA, alanine aminotransferase levels and well-being in patients with CHC...
  14. ncbi request reprint GB virus C: insights into co-infection
    Mark D Berzsenyi
    Department of Gastroenterology, Alfred Hospital, Commercial Road, Prahran 3181, Victoria, Australia
    J Clin Virol 33:257-66. 2005
    ..Elucidation of the putative protective effect of GBV-C in HIV co-infection could potentially identify novel targets for anti-HIV therapeutics and lead to the development of disease modifying vaccines...
  15. ncbi request reprint Genomics of hepatitis B and C infections: diagnostic and therapeutic applications of microarray profiling
    Mark D Berzsenyi
    Department of Gastroenterology, Alfred Hospital, Victoria, Australia
    Antivir Ther 11:541-52. 2006
    ..Thus, microarray profiling offers enormous potential for improvements in antiviral therapy and our understanding of blood-borne viral hepatitis...
  16. ncbi request reprint Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis
    Adam Gordon
    Department of Gastroenterology, The Alfred Hospital, Commercial Road, Prahran 3181, Vic, Australia
    J Hepatol 43:38-44. 2005
    ..Chronic hepatitis B (CHB) and C (CHC) are commonly associated with hepatic steatosis. The aims of this study were to investigate predictors of hepatic steatosis, and their impact on inflammation and fibrosis in CHB and CHC...
  17. doi request reprint Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial
    William Kemp
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
    Liver Int 29:427-33. 2009
    ..Aims: To examine the impact of SID with norfloxacin on portal pressure in subjects with clinically significant portal hypertension and explore the potential mechanisms by which norfloxacin exerts its haemodynamic effects...
  18. ncbi request reprint Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension
    William Kemp
    Department Gastroenterology, Alfred Hospital, Melbourne, Australia
    Liver Int 27:1232-9. 2007
    ..Urotensin II (UII) is recognised as the most potent human vasoconstrictor; however, its role in chronic liver disease (CLD) is unknown...
  19. ncbi request reprint Increased circulating urotensin II in cirrhosis: potential implications in liver disease
    William Kemp
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
    Peptides 29:868-72. 2008
    ..In this review we focus on the potential relevance of UII as a vasoactive mediator in the chronic liver disease population and postulate as to the site of overproduction of UII...
  20. doi request reprint Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats
    William Kemp
    Department of Epidemiology and Preventive Medicine, Monash University, Prahran, Victoria, Australia
    Am J Physiol Gastrointest Liver Physiol 297:G762-7. 2009
    ..This response may be mediated via induction of fibrogenic cytokines. These findings have pathophysiological implications in human liver disease where increased plasma UII levels have been observed...
  21. ncbi request reprint Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation
    Brenda M Button
    Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, Melbourne, Australia
    J Heart Lung Transplant 24:1522-9. 2005
    ..The significance of gastroesophageal reflux (GER) and aspiration are unclear in cystic fibrosis (CF) and may contribute to declining lung function before and after lung transplantation (LTx)...
  22. ncbi request reprint Urotensin II in chronic liver disease: in vivo effect on vascular tone
    William Kemp
    Department of Gastroenterology, Alfred Hospital, Melbourne, Australia
    Scand J Gastroenterol 43:103-9. 2008
    ..The objective of this study was to investigate the role of UII in liver cirrhosis via examination of the in vivo effect of UII in this patient group...
  23. doi request reprint Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease
    Matthew T Kitson
    Department of Gastroenterology, Alfred Hospital, Melbourne, Australia
    Liver Int 33:698-705. 2013
    ..Liver biopsy is rarely performed because of the patchy nature of the disease. Transient elastography can reliably stage liver fibrosis via liver stiffness measurement (LSM)...
  24. doi request reprint D-livering the message: the importance of vitamin D status in chronic liver disease
    Matthew T Kitson
    Department of Gastroenterology, The Alfred, Melbourne, Australia
    J Hepatol 57:897-909. 2012
    ..Further prospective studies are therefore warranted to investigate the therapeutic impact of vitamin D supplementation in chronic liver disease...
  25. doi request reprint Non-cirrhotic portal hypertension in HIV mono-infected patients
    Belinda D Jackson
    Department of Gastroenterology, The Alfred Hospital Infectious Diseases Unit, The Alfred Hospital, Australia
    J Gastroenterol Hepatol 27:1512-9. 2012
    ..We describe a series of HIV mono-infected patients with evidence of non-cirrhotic portal hypertension...
  26. pmc Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease
    Christopher P Desmond
    Department of Gastroenterology, The Alfred, Melbourne, Australia
    J Virol 86:1181-92. 2012
    ..003). Thus, HBV appears to be under immune pressure in chronic HBV infection, particularly in HBeAg-negative disease...
  27. ncbi request reprint Male to male sex is associated with a high prevalence of exposure to GB virus C
    Mark D Berzsenyi
    Department of Gastroenterology and Hepatology, Alfred Hospital, Commercial Road, Prahran, 3181 Vic, Australia
    J Clin Virol 33:243-6. 2005
    ..As male to male sex is also a risk factor for HIV transmission our data suggest that many may benefit from the potential protective effect GBV-C exerts on HIV-infected persons...
  28. ncbi request reprint Extramedullary relapse of multiple myeloma presenting as hematemesis and melena
    Mark A Dawson
    Department of Haematology and Bone Marrow Transplantation, The Alfred Hospital, Commercial Road, Prahran, Melbourne, Victoria 3181, Australia
    Nat Clin Pract Oncol 3:223-6; quiz 227. 2006
    ..She presented with hematemesis and melena following salvage chemotherapy with dexamethasone, cyclophosphamide, etoposide, cisplatin, and rescue therapy with single-agent bortezomib...
  29. pmc Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection
    Shuo Li
    Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
    PLoS Pathog 5:e1000707. 2009
    ..Some reactive peptides overlapped with previously described effector T cell epitopes. Our data offers new insights into HCV immune evasion and tolerance, and highlights the non-self specific nature of Treg during infection...
  30. ncbi request reprint What is the role of GB virus C infection in hepatitis C virus/HIV coinfection?
    Mark D Berzsenyi
    J Infect Dis 194:407-9. 2006
  31. ncbi request reprint Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy
    Adam Gordon
    Nephrol Dial Transplant 19:2155. 2004
  32. ncbi request reprint The direct cost of managing patients with chronic hepatitis B infection in Australia
    James R G Butler
    National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia
    J Clin Gastroenterol 38:S187-92. 2004
    ..To estimate the average annual cost of managing a patient with chronic hepatitis B (CHB) disease in Australia...
  33. ncbi request reprint Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine
    Simon A Zanati
    Department of Gastroenterology and Hepatology, The Alfred Hospital, Commercial Road, Prahran, VIC 3181, Australia
    J Clin Virol 31:53-7. 2004
    ..As in the transplantation setting, viral DNA levels should be kept to undetectable if viral replication or recurrence is to be prevented...
  34. ncbi request reprint Steroid-responsive catastrophic antiphospholipid syndrome
    Adam Gordon
    J Gastroenterol Hepatol 19:479-80. 2004